ID   PTN1_HUMAN              Reviewed;         435 AA.
AC   P18031; Q5TGD8; Q9BQV9; Q9NQQ4;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 1.
DT   10-MAY-2017, entry version 214.
DE   RecName: Full=Tyrosine-protein phosphatase non-receptor type 1;
DE            EC=3.1.3.48;
DE   AltName: Full=Protein-tyrosine phosphatase 1B;
DE            Short=PTP-1B;
GN   Name=PTPN1; Synonyms=PTP1B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=2157211; DOI=10.1073/pnas.87.7.2735;
RA   Chernoff J., Schievella A.R., Jost C.A., Erikson R.L., Neel B.G.;
RT   "Cloning of a cDNA for a major human protein-tyrosine-phosphatase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:2735-2739(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   TISSUE=Placenta;
RX   PubMed=2164224; DOI=10.1073/pnas.87.13.5148;
RA   Brown-Shimer S., Johnson K.A., Lawrence J.B., Johnson C., Bruskin A.,
RA   Green N.R., Hill D.E.;
RT   "Molecular cloning and chromosome mapping of the human gene encoding
RT   protein phosphotyrosyl phosphatase 1B.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:5148-5152(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 1-321, AND ACETYLATION AT MET-1.
RC   TISSUE=Placenta;
RX   PubMed=2546149; DOI=10.1073/pnas.86.14.5252;
RA   Charbonneau H., Tonks N.K., Kumar S., Diltz C.D., Harrylock M.,
RA   Cool D.E., Krebs E.G., Fischer E.H., Walsh K.A.;
RT   "Human placenta protein-tyrosine-phosphatase: amino acid sequence and
RT   relationship to a family of receptor-like proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:5252-5256(1989).
RN   [7]
RP   PHOSPHORYLATION AT SER-352; SER-378 AND SER-386.
RX   PubMed=8491187;
RA   Flint A.J., Gebbink M.F.G.B., Franza B.R. Jr., Hill D.E., Tonks N.K.;
RT   "Multi-site phosphorylation of the protein tyrosine phosphatase,
RT   PTP1B: identification of cell cycle regulated and phorbol ester
RT   stimulated sites of phosphorylation.";
RL   EMBO J. 12:1937-1946(1993).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=1739967; DOI=10.1016/0092-8674(92)90190-N;
RA   Frangioni J.V., Beahm P.H., Shifrin V., Jost C.A., Neel B.G.;
RT   "The nontransmembrane tyrosine phosphatase PTP-1B localizes to the
RT   endoplasmic reticulum via its 35 amino acid C-terminal sequence.";
RL   Cell 68:545-560(1992).
RN   [9]
RP   PHOSPHORYLATION AT TYR-66.
RX   PubMed=9355745; DOI=10.1042/bj3270139;
RA   Liu F., Chernoff J.;
RT   "Protein tyrosine phosphatase 1B interacts with and is tyrosine
RT   phosphorylated by the epidermal growth factor receptor.";
RL   Biochem. J. 327:139-145(1997).
RN   [10]
RP   PHOSPHORYLATION AT SER-50; SER-242 AND SER-243, AND MUTAGENESIS OF
RP   SER-50.
RX   PubMed=10480872; DOI=10.1074/jbc.274.38.26697;
RA   Moeslein F.M., Myers M.P., Landreth G.E.;
RT   "The CLK family kinases, CLK1 and CLK2, phosphorylate and activate the
RT   tyrosine phosphatase, PTP-1B.";
RL   J. Biol. Chem. 274:26697-26704(1999).
RN   [11]
RP   PHOSPHORYLATION AT SER-50, AND MUTAGENESIS OF SER-50.
RX   PubMed=11579209; DOI=10.1210/mend.15.10.0711;
RA   Ravichandran L.V., Chen H., Li Y., Quon M.J.;
RT   "Phosphorylation of PTP1B at Ser(50) by Akt impairs its ability to
RT   dephosphorylate the insulin receptor.";
RL   Mol. Endocrinol. 15:1768-1780(2001).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-20, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [13]
RP   FUNCTION IN DEPHOSPHORYLATION OF MET, AND INTERACTION WITH MET.
RX   PubMed=18819921; DOI=10.1074/jbc.M805916200;
RA   Sangwan V., Paliouras G.N., Abella J.V., Dube N., Monast A.,
RA   Tremblay M.L., Park M.;
RT   "Regulation of the Met receptor-tyrosine kinase by the protein-
RT   tyrosine phosphatase 1B and T-cell phosphatase.";
RL   J. Biol. Chem. 283:34374-34383(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-352, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [15]
RP   INTERACTION WITH EPHA3, FUNCTION IN EPHA3 DEPHOSPHORYLATION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=21135139; DOI=10.1083/jcb.201005035;
RA   Nievergall E., Janes P.W., Stegmayer C., Vail M.E., Haj F.G.,
RA   Teng S.W., Neel B.G., Bastiaens P.I., Lackmann M.;
RT   "PTP1B regulates Eph receptor function and trafficking.";
RL   J. Cell Biol. 191:1189-1203(2010).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-352, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   FUNCTION, SULFHYDRATION AT CYS-215, S-NITROSYLATION AT CYS-215,
RP   MUTAGENESIS OF CYS-215, AND MUTAGENESIS OF ASP-181 AND CYS-215.
RX   PubMed=22169477; DOI=10.1126/scisignal.2002329;
RA   Krishnan N., Fu C., Pappin D.J., Tonks N.K.;
RT   "H2s-induced sulfhydration of the phosphatase PTP1B and its role in
RT   the endoplasmic reticulum stress response.";
RL   Sci. Signal. 4:RA86-RA86(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-378, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-50; SER-352; SER-363;
RP   SER-365; THR-368; SER-378 AND SER-386, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1-321.
RX   PubMed=8128219; DOI=10.1126/science.8128219;
RA   Barford D., Flint A.J., Tonks N.K.;
RT   "Crystal structure of human protein tyrosine phosphatase 1B.";
RL   Science 263:1397-1404(1994).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 1-298 OF MUTANT SER-215.
RX   PubMed=9391040; DOI=10.1073/pnas.94.25.13420;
RA   Puius Y.A., Zhao Y., Sullivan M., Lawrence D.S., Almo S.C.,
RA   Zhang Z.Y.;
RT   "Identification of a second aryl phosphate-binding site in protein-
RT   tyrosine phosphatase 1B: a paradigm for inhibitor design.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:13420-13425(1997).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-285.
RX   PubMed=9553104; DOI=10.1074/jbc.273.17.10454;
RA   Pannifer A.D., Flint A.J., Tonks N.K., Barford D.;
RT   "Visualization of the cysteinyl-phosphate intermediate of a protein-
RT   tyrosine phosphatase by X-ray crystallography.";
RL   J. Biol. Chem. 273:10454-10462(1998).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 1-298.
RX   PubMed=9922143; DOI=10.1021/bi9816958;
RA   Groves M.R., Yao Z.-J., Roller P.P., Burke T.R. Jr., Barford D.;
RT   "Structural basis for inhibition of the protein tyrosine phosphatase
RT   1B by phosphotyrosine peptide mimetics.";
RL   Biochemistry 37:17773-17783(1998).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1-321, OXIDATION AT CYS-215,
RP   AND CROSS-LINK 215-CYS-SER-216.
RX   PubMed=12802338; DOI=10.1038/nature01680;
RA   Salmeen A., Andersen J.N., Myers M.P., Meng T.-C., Hinks J.A.,
RA   Tonks N.K., Barford D.;
RT   "Redox regulation of protein tyrosine phosphatase 1B involves a
RT   sulphenyl-amide intermediate.";
RL   Nature 423:769-773(2003).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1-321, OXIDATION AT CYS-215,
RP   AND CROSS-LINK 215-CYS-SER-216.
RX   PubMed=12802339; DOI=10.1038/nature01681;
RA   Van Montfort R.L.M., Congreve M., Tisi D., Carr R., Jhoti H.;
RT   "Oxidation state of the active-site cysteine in protein tyrosine
RT   phosphatase 1B.";
RL   Nature 423:773-777(2003).
RN   [27]
RP   ASSOCIATION OF VARIANT LEU-387 WITH LOW GLUCOSE TOLERANCE.
RX   PubMed=15919835; DOI=10.1038/oby.2005.95;
RA   Ukkola O., Rankinen T., Lakka T., Leon A.S., Skinner J.S.,
RA   Wilmore J.H., Rao D.C., Kesaeniemi Y.A., Bouchard C.;
RT   "Protein tyrosine phosphatase 1B variant associated with fat
RT   distribution and insulin metabolism.";
RL   Obes. Res. 13:829-834(2005).
CC   -!- FUNCTION: Tyrosine-protein phosphatase which acts as a regulator
CC       of endoplasmic reticulum unfolded protein response. Mediates
CC       dephosphorylation of EIF2AK3/PERK; inactivating the protein kinase
CC       activity of EIF2AK3/PERK. May play an important role in CKII- and
CC       p60c-src-induced signal transduction cascades. May regulate the
CC       EFNA5-EPHA3 signaling pathway which modulates cell reorganization
CC       and cell-cell repulsion. May also regulate the hepatocyte growth
CC       factor receptor signaling pathway through dephosphorylation of
CC       MET. {ECO:0000269|PubMed:18819921, ECO:0000269|PubMed:21135139,
CC       ECO:0000269|PubMed:22169477}.
CC   -!- CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein
CC       tyrosine + phosphate. {ECO:0000255|PROSITE-ProRule:PRU10044}.
CC   -!- SUBUNIT: Interacts with EPHA3 (phosphorylated); dephosphorylates
CC       EPHA3 and may regulate its trafficking and function. Interacts
CC       with MET. {ECO:0000269|PubMed:18819921,
CC       ECO:0000269|PubMed:21135139}.
CC   -!- INTERACTION:
CC       P56945:BCAR1; NbExp=5; IntAct=EBI-968788, EBI-702093;
CC       Q61140:Bcar1 (xeno); NbExp=5; IntAct=EBI-968788, EBI-77088;
CC       Q63767:Bcar1 (xeno); NbExp=5; IntAct=EBI-968788, EBI-1176801;
CC       P11274-1:BCR; NbExp=3; IntAct=EBI-968788, EBI-8658094;
CC       P07384:CAPN1; NbExp=4; IntAct=EBI-968788, EBI-1542113;
CC       Q03135:CAV1; NbExp=5; IntAct=EBI-968788, EBI-603614;
CC       P15116:Cdh2 (xeno); NbExp=3; IntAct=EBI-968788, EBI-397974;
CC       Q63768:Crk (xeno); NbExp=2; IntAct=EBI-968788, EBI-8423843;
CC       Q14247:CTTN; NbExp=2; IntAct=EBI-968788, EBI-351886;
CC       P00533:EGFR; NbExp=7; IntAct=EBI-968788, EBI-297353;
CC       P19235:EPOR; NbExp=3; IntAct=EBI-968788, EBI-617321;
CC       P10912:GHR; NbExp=5; IntAct=EBI-968788, EBI-286316;
CC       P62993:GRB2; NbExp=2; IntAct=EBI-968788, EBI-401755;
CC       P62994:Grb2 (xeno); NbExp=3; IntAct=EBI-968788, EBI-401775;
CC       P08069:IGF1R; NbExp=3; IntAct=EBI-968788, EBI-475981;
CC       P06213:INSR; NbExp=33; IntAct=EBI-968788, EBI-475899;
CC       P35570:Irs1 (xeno); NbExp=3; IntAct=EBI-968788, EBI-520230;
CC       P05556:ITGB1; NbExp=2; IntAct=EBI-968788, EBI-703066;
CC       P05106:ITGB3; NbExp=4; IntAct=EBI-968788, EBI-702847;
CC       O60674:JAK2; NbExp=5; IntAct=EBI-968788, EBI-518647;
CC       O43561:LAT; NbExp=3; IntAct=EBI-968788, EBI-1222766;
CC       P08581:MET; NbExp=3; IntAct=EBI-968788, EBI-1039152;
CC       P04629:NTRK1; NbExp=2; IntAct=EBI-968788, EBI-1028226;
CC       P09619:PDGFRB; NbExp=3; IntAct=EBI-968788, EBI-641237;
CC       P05622:Pdgfrb (xeno); NbExp=3; IntAct=EBI-968788, EBI-1554855;
CC       P10686:Plcg1 (xeno); NbExp=4; IntAct=EBI-968788, EBI-520788;
CC       P34152:Ptk2 (xeno); NbExp=2; IntAct=EBI-968788, EBI-77070;
CC       Q8VI36:Pxn (xeno); NbExp=2; IntAct=EBI-968788, EBI-983394;
CC       Q96TC7:RMDN3; NbExp=4; IntAct=EBI-968788, EBI-1056589;
CC       P08922:ROS1; NbExp=3; IntAct=EBI-968788, EBI-7371065;
CC       P12931:SRC; NbExp=14; IntAct=EBI-968788, EBI-621482;
CC       P40763:STAT3; NbExp=2; IntAct=EBI-968788, EBI-518675;
CC       P42229:STAT5A; NbExp=2; IntAct=EBI-968788, EBI-749537;
CC       P63166:Sumo1 (xeno); NbExp=2; IntAct=EBI-968788, EBI-80152;
CC       Q9H1D0:TRPV6; NbExp=6; IntAct=EBI-968788, EBI-7198335;
CC       P10599:TXN; NbExp=2; IntAct=EBI-968788, EBI-594644;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:1739967, ECO:0000269|PubMed:21135139};
CC       Peripheral membrane protein {ECO:0000269|PubMed:1739967,
CC       ECO:0000269|PubMed:21135139}; Cytoplasmic side
CC       {ECO:0000269|PubMed:1739967, ECO:0000269|PubMed:21135139}.
CC       Note=Interacts with EPHA3 at the cell membrane.
CC   -!- PTM: Oxidized on Cys-215; the Cys-SOH formed in response to redox
CC       signaling reacts with the alpha-amido of the following residue to
CC       form a sulfenamide cross-link, triggering a conformational change
CC       that inhibits substrate binding and activity. The active site can
CC       be restored by reduction. {ECO:0000269|PubMed:12802338,
CC       ECO:0000269|PubMed:12802339}.
CC   -!- PTM: Ser-50 is the major site of phosphorylation as compared to
CC       Ser-242 and Ser-243. Activated by phosphorylation at Ser-50.
CC       {ECO:0000269|PubMed:10480872, ECO:0000269|PubMed:11579209,
CC       ECO:0000269|PubMed:8491187, ECO:0000269|PubMed:9355745}.
CC   -!- PTM: S-nitrosylation of Cys-215 inactivates the enzyme activity.
CC       {ECO:0000269|PubMed:22169477}.
CC   -!- PTM: Sulfhydration at Cys-215 following endoplasmic reticulum
CC       stress inactivates the enzyme activity, promoting EIF2AK3/PERK
CC       activity.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family.
CC       Non-receptor class 1 subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PTPN1ID41909ch20q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M31724; AAA60223.1; -; mRNA.
DR   EMBL; M33689; AAA60157.1; -; mRNA.
DR   EMBL; M33684; AAA60158.1; -; Genomic_DNA.
DR   EMBL; M33688; AAA60158.1; JOINED; Genomic_DNA.
DR   EMBL; M33687; AAA60158.1; JOINED; Genomic_DNA.
DR   EMBL; M33686; AAA60158.1; JOINED; Genomic_DNA.
DR   EMBL; M33685; AAA60158.1; JOINED; Genomic_DNA.
DR   EMBL; BT006752; AAP35398.1; -; mRNA.
DR   EMBL; AL133230; CAC00618.2; -; Genomic_DNA.
DR   EMBL; AL034429; CAC00618.2; JOINED; Genomic_DNA.
DR   EMBL; AL034429; CAI23215.1; -; Genomic_DNA.
DR   EMBL; AL133230; CAI23215.1; JOINED; Genomic_DNA.
DR   EMBL; BC015660; AAH15660.1; -; mRNA.
DR   EMBL; BC018164; AAH18164.1; -; mRNA.
DR   CCDS; CCDS13430.1; -.
DR   PIR; A35992; TPHUN1.
DR   RefSeq; NP_001265547.1; NM_001278618.1.
DR   RefSeq; NP_002818.1; NM_002827.3.
DR   UniGene; Hs.417549; -.
DR   PDB; 1A5Y; X-ray; 2.50 A; A=1-330.
DR   PDB; 1AAX; X-ray; 1.90 A; A=1-321.
DR   PDB; 1BZC; X-ray; 2.35 A; A=1-321.
DR   PDB; 1BZH; X-ray; 2.10 A; A=1-298.
DR   PDB; 1BZJ; X-ray; 2.25 A; A=2-298.
DR   PDB; 1C83; X-ray; 1.80 A; A=1-298.
DR   PDB; 1C84; X-ray; 2.35 A; A=1-298.
DR   PDB; 1C85; X-ray; 2.72 A; A=1-298.
DR   PDB; 1C86; X-ray; 2.30 A; A=1-298.
DR   PDB; 1C87; X-ray; 2.10 A; A=1-298.
DR   PDB; 1C88; X-ray; 1.80 A; A=1-298.
DR   PDB; 1ECV; X-ray; 1.95 A; A=1-298.
DR   PDB; 1EEN; X-ray; 1.90 A; A=1-321.
DR   PDB; 1EEO; X-ray; 1.80 A; A=1-321.
DR   PDB; 1G1F; X-ray; 2.00 A; A=1-298.
DR   PDB; 1G1G; X-ray; 2.20 A; A=1-298.
DR   PDB; 1G1H; X-ray; 2.40 A; A=1-298.
DR   PDB; 1G7F; X-ray; 1.80 A; A=1-298.
DR   PDB; 1G7G; X-ray; 2.20 A; A=1-298.
DR   PDB; 1GFY; X-ray; 2.13 A; A=1-298.
DR   PDB; 1I57; X-ray; 2.10 A; A=1-298.
DR   PDB; 1JF7; X-ray; 2.20 A; A/B=1-298.
DR   PDB; 1KAK; X-ray; 2.50 A; A=1-298.
DR   PDB; 1KAV; X-ray; 2.35 A; A=1-298.
DR   PDB; 1L8G; X-ray; 2.50 A; A=1-321.
DR   PDB; 1LQF; X-ray; 2.50 A; A/B/C/D=1-283.
DR   PDB; 1NL9; X-ray; 2.40 A; A=1-321.
DR   PDB; 1NNY; X-ray; 2.40 A; A=1-321.
DR   PDB; 1NO6; X-ray; 2.40 A; A=1-321.
DR   PDB; 1NWE; X-ray; 3.10 A; A=1-298.
DR   PDB; 1NWL; X-ray; 2.40 A; A=1-298.
DR   PDB; 1NZ7; X-ray; 2.40 A; A=1-321.
DR   PDB; 1OEM; X-ray; 1.80 A; X=1-321.
DR   PDB; 1OEO; X-ray; 2.15 A; X=1-321.
DR   PDB; 1OES; X-ray; 2.20 A; A=1-321.
DR   PDB; 1OET; X-ray; 2.30 A; A=1-321.
DR   PDB; 1OEU; X-ray; 2.50 A; A=1-321.
DR   PDB; 1OEV; X-ray; 2.20 A; A=1-321.
DR   PDB; 1ONY; X-ray; 2.15 A; A=1-321.
DR   PDB; 1ONZ; X-ray; 2.40 A; A=1-321.
DR   PDB; 1PA1; X-ray; 1.60 A; A=1-298.
DR   PDB; 1PH0; X-ray; 2.20 A; A=1-321.
DR   PDB; 1PTT; X-ray; 2.90 A; A=1-321.
DR   PDB; 1PTU; X-ray; 2.60 A; A=1-321.
DR   PDB; 1PTV; X-ray; 2.30 A; A=1-321.
DR   PDB; 1PTY; X-ray; 1.85 A; A=1-321.
DR   PDB; 1PXH; X-ray; 2.15 A; A=1-321.
DR   PDB; 1PYN; X-ray; 2.20 A; A=1-321.
DR   PDB; 1Q1M; X-ray; 2.60 A; A=1-321.
DR   PDB; 1Q6J; X-ray; 2.20 A; A=1-298.
DR   PDB; 1Q6M; X-ray; 2.20 A; A=1-298.
DR   PDB; 1Q6N; X-ray; 2.10 A; A/B=1-298.
DR   PDB; 1Q6P; X-ray; 2.30 A; A/B=1-298.
DR   PDB; 1Q6S; X-ray; 2.20 A; A/B=1-298.
DR   PDB; 1Q6T; X-ray; 2.30 A; A/B=1-298.
DR   PDB; 1QXK; X-ray; 2.30 A; A=1-321.
DR   PDB; 1SUG; X-ray; 1.95 A; A=1-321.
DR   PDB; 1T48; X-ray; 2.20 A; A=1-298.
DR   PDB; 1T49; X-ray; 1.90 A; A=1-298.
DR   PDB; 1T4J; X-ray; 2.70 A; A=1-298.
DR   PDB; 1WAX; X-ray; 2.20 A; A=1-321.
DR   PDB; 1XBO; X-ray; 2.50 A; A=1-321.
DR   PDB; 2AZR; X-ray; 2.00 A; A=1-299.
DR   PDB; 2B07; X-ray; 2.10 A; A=1-299.
DR   PDB; 2B4S; X-ray; 2.30 A; A/C=1-298.
DR   PDB; 2BGD; X-ray; 2.40 A; A=1-321.
DR   PDB; 2BGE; X-ray; 1.80 A; A=1-321.
DR   PDB; 2CM2; X-ray; 1.50 A; A=2-298.
DR   PDB; 2CM3; X-ray; 2.10 A; A/B=1-298.
DR   PDB; 2CM7; X-ray; 2.10 A; A=1-321.
DR   PDB; 2CM8; X-ray; 2.10 A; A=1-321.
DR   PDB; 2CMA; X-ray; 2.30 A; A=1-321.
DR   PDB; 2CMB; X-ray; 1.70 A; A=1-298.
DR   PDB; 2CMC; X-ray; 2.20 A; A=1-298.
DR   PDB; 2CNE; X-ray; 1.80 A; A=1-298.
DR   PDB; 2CNF; X-ray; 2.20 A; A=1-321.
DR   PDB; 2CNG; X-ray; 1.90 A; A=1-321.
DR   PDB; 2CNH; X-ray; 1.80 A; A=1-321.
DR   PDB; 2CNI; X-ray; 2.00 A; A=1-321.
DR   PDB; 2F6F; X-ray; 2.00 A; A=1-298.
DR   PDB; 2F6T; X-ray; 1.70 A; A=1-298.
DR   PDB; 2F6V; X-ray; 1.70 A; A=1-298.
DR   PDB; 2F6W; X-ray; 2.20 A; A=1-298.
DR   PDB; 2F6Y; X-ray; 2.15 A; A=1-298.
DR   PDB; 2F6Z; X-ray; 1.70 A; A=1-298.
DR   PDB; 2F70; X-ray; 2.12 A; A=1-298.
DR   PDB; 2F71; X-ray; 1.55 A; A=1-298.
DR   PDB; 2FJM; X-ray; 2.10 A; A/B=1-298.
DR   PDB; 2FJN; X-ray; 2.20 A; A/B=1-298.
DR   PDB; 2H4G; X-ray; 2.50 A; A=1-299.
DR   PDB; 2H4K; X-ray; 2.30 A; A=1-299.
DR   PDB; 2HB1; X-ray; 2.00 A; A=1-299.
DR   PDB; 2HNP; X-ray; 2.85 A; A=1-321.
DR   PDB; 2HNQ; X-ray; 2.85 A; A=1-321.
DR   PDB; 2NT7; X-ray; 2.10 A; A=1-299.
DR   PDB; 2NTA; X-ray; 2.10 A; A=1-299.
DR   PDB; 2QBP; X-ray; 2.50 A; A=1-299.
DR   PDB; 2QBQ; X-ray; 2.10 A; A=1-299.
DR   PDB; 2QBR; X-ray; 2.30 A; A=1-299.
DR   PDB; 2QBS; X-ray; 2.10 A; A=1-299.
DR   PDB; 2VEU; X-ray; 2.40 A; A=1-321.
DR   PDB; 2VEV; X-ray; 1.80 A; A=1-321.
DR   PDB; 2VEW; X-ray; 2.00 A; A=1-321.
DR   PDB; 2VEX; X-ray; 2.20 A; A=1-321.
DR   PDB; 2VEY; X-ray; 2.20 A; A=1-321.
DR   PDB; 2ZMM; X-ray; 2.10 A; A=1-299.
DR   PDB; 2ZN7; X-ray; 2.10 A; A=1-299.
DR   PDB; 3A5J; X-ray; 1.70 A; A=2-321.
DR   PDB; 3A5K; X-ray; 1.85 A; A=2-298.
DR   PDB; 3CWE; X-ray; 1.60 A; A=1-283.
DR   PDB; 3D9C; X-ray; 2.30 A; A=1-321.
DR   PDB; 3EAX; X-ray; 1.90 A; A=1-321.
DR   PDB; 3EB1; X-ray; 2.40 A; A=1-321.
DR   PDB; 3EU0; X-ray; 2.70 A; A=1-282.
DR   PDB; 3I7Z; X-ray; 2.30 A; A=1-321.
DR   PDB; 3I80; X-ray; 2.25 A; A=1-321.
DR   PDB; 3QKP; X-ray; 2.05 A; A=1-321.
DR   PDB; 3QKQ; X-ray; 2.20 A; A=1-321.
DR   PDB; 3SME; X-ray; 1.70 A; A=1-298.
DR   PDB; 3ZMP; X-ray; 2.62 A; A/B=1-321.
DR   PDB; 3ZMQ; X-ray; 3.30 A; A=1-321.
DR   PDB; 3ZV2; X-ray; 2.80 A; A=1-320.
DR   PDB; 4BJO; X-ray; 2.06 A; A/B=2-321.
DR   PDB; 4I8N; X-ray; 2.50 A; A=1-320.
DR   PDB; 4QAH; X-ray; 2.40 A; A=1-299.
DR   PDB; 4QAP; X-ray; 1.90 A; A=1-299.
DR   PDB; 4QBE; X-ray; 2.29 A; A=1-298.
DR   PDB; 4QBW; X-ray; 1.91 A; A=1-299.
DR   PDB; 4Y14; X-ray; 1.90 A; A/B=2-301.
DR   PDB; 4ZRT; X-ray; 1.74 A; A=1-298.
DR   PDB; 5K9V; X-ray; 1.90 A; A=1-301.
DR   PDB; 5K9W; X-ray; 2.01 A; A=1-301.
DR   PDB; 5KA0; X-ray; 1.99 A; A=1-284.
DR   PDB; 5KA1; X-ray; 1.84 A; A=1-284.
DR   PDB; 5KA2; X-ray; 2.07 A; A=1-301.
DR   PDB; 5KA3; X-ray; 2.14 A; A=1-301.
DR   PDB; 5KA4; X-ray; 2.19 A; A=1-301.
DR   PDB; 5KA7; X-ray; 2.06 A; A=1-301.
DR   PDB; 5KA8; X-ray; 1.97 A; A=1-301.
DR   PDB; 5KA9; X-ray; 2.07 A; A=1-301.
DR   PDB; 5KAA; X-ray; 1.97 A; A=1-284.
DR   PDB; 5KAB; X-ray; 1.97 A; A=1-284.
DR   PDB; 5KAC; X-ray; 1.90 A; A=1-301.
DR   PDB; 5KAD; X-ray; 1.90 A; A/B=1-301.
DR   PDBsum; 1A5Y; -.
DR   PDBsum; 1AAX; -.
DR   PDBsum; 1BZC; -.
DR   PDBsum; 1BZH; -.
DR   PDBsum; 1BZJ; -.
DR   PDBsum; 1C83; -.
DR   PDBsum; 1C84; -.
DR   PDBsum; 1C85; -.
DR   PDBsum; 1C86; -.
DR   PDBsum; 1C87; -.
DR   PDBsum; 1C88; -.
DR   PDBsum; 1ECV; -.
DR   PDBsum; 1EEN; -.
DR   PDBsum; 1EEO; -.
DR   PDBsum; 1G1F; -.
DR   PDBsum; 1G1G; -.
DR   PDBsum; 1G1H; -.
DR   PDBsum; 1G7F; -.
DR   PDBsum; 1G7G; -.
DR   PDBsum; 1GFY; -.
DR   PDBsum; 1I57; -.
DR   PDBsum; 1JF7; -.
DR   PDBsum; 1KAK; -.
DR   PDBsum; 1KAV; -.
DR   PDBsum; 1L8G; -.
DR   PDBsum; 1LQF; -.
DR   PDBsum; 1NL9; -.
DR   PDBsum; 1NNY; -.
DR   PDBsum; 1NO6; -.
DR   PDBsum; 1NWE; -.
DR   PDBsum; 1NWL; -.
DR   PDBsum; 1NZ7; -.
DR   PDBsum; 1OEM; -.
DR   PDBsum; 1OEO; -.
DR   PDBsum; 1OES; -.
DR   PDBsum; 1OET; -.
DR   PDBsum; 1OEU; -.
DR   PDBsum; 1OEV; -.
DR   PDBsum; 1ONY; -.
DR   PDBsum; 1ONZ; -.
DR   PDBsum; 1PA1; -.
DR   PDBsum; 1PH0; -.
DR   PDBsum; 1PTT; -.
DR   PDBsum; 1PTU; -.
DR   PDBsum; 1PTV; -.
DR   PDBsum; 1PTY; -.
DR   PDBsum; 1PXH; -.
DR   PDBsum; 1PYN; -.
DR   PDBsum; 1Q1M; -.
DR   PDBsum; 1Q6J; -.
DR   PDBsum; 1Q6M; -.
DR   PDBsum; 1Q6N; -.
DR   PDBsum; 1Q6P; -.
DR   PDBsum; 1Q6S; -.
DR   PDBsum; 1Q6T; -.
DR   PDBsum; 1QXK; -.
DR   PDBsum; 1SUG; -.
DR   PDBsum; 1T48; -.
DR   PDBsum; 1T49; -.
DR   PDBsum; 1T4J; -.
DR   PDBsum; 1WAX; -.
DR   PDBsum; 1XBO; -.
DR   PDBsum; 2AZR; -.
DR   PDBsum; 2B07; -.
DR   PDBsum; 2B4S; -.
DR   PDBsum; 2BGD; -.
DR   PDBsum; 2BGE; -.
DR   PDBsum; 2CM2; -.
DR   PDBsum; 2CM3; -.
DR   PDBsum; 2CM7; -.
DR   PDBsum; 2CM8; -.
DR   PDBsum; 2CMA; -.
DR   PDBsum; 2CMB; -.
DR   PDBsum; 2CMC; -.
DR   PDBsum; 2CNE; -.
DR   PDBsum; 2CNF; -.
DR   PDBsum; 2CNG; -.
DR   PDBsum; 2CNH; -.
DR   PDBsum; 2CNI; -.
DR   PDBsum; 2F6F; -.
DR   PDBsum; 2F6T; -.
DR   PDBsum; 2F6V; -.
DR   PDBsum; 2F6W; -.
DR   PDBsum; 2F6Y; -.
DR   PDBsum; 2F6Z; -.
DR   PDBsum; 2F70; -.
DR   PDBsum; 2F71; -.
DR   PDBsum; 2FJM; -.
DR   PDBsum; 2FJN; -.
DR   PDBsum; 2H4G; -.
DR   PDBsum; 2H4K; -.
DR   PDBsum; 2HB1; -.
DR   PDBsum; 2HNP; -.
DR   PDBsum; 2HNQ; -.
DR   PDBsum; 2NT7; -.
DR   PDBsum; 2NTA; -.
DR   PDBsum; 2QBP; -.
DR   PDBsum; 2QBQ; -.
DR   PDBsum; 2QBR; -.
DR   PDBsum; 2QBS; -.
DR   PDBsum; 2VEU; -.
DR   PDBsum; 2VEV; -.
DR   PDBsum; 2VEW; -.
DR   PDBsum; 2VEX; -.
DR   PDBsum; 2VEY; -.
DR   PDBsum; 2ZMM; -.
DR   PDBsum; 2ZN7; -.
DR   PDBsum; 3A5J; -.
DR   PDBsum; 3A5K; -.
DR   PDBsum; 3CWE; -.
DR   PDBsum; 3D9C; -.
DR   PDBsum; 3EAX; -.
DR   PDBsum; 3EB1; -.
DR   PDBsum; 3EU0; -.
DR   PDBsum; 3I7Z; -.
DR   PDBsum; 3I80; -.
DR   PDBsum; 3QKP; -.
DR   PDBsum; 3QKQ; -.
DR   PDBsum; 3SME; -.
DR   PDBsum; 3ZMP; -.
DR   PDBsum; 3ZMQ; -.
DR   PDBsum; 3ZV2; -.
DR   PDBsum; 4BJO; -.
DR   PDBsum; 4I8N; -.
DR   PDBsum; 4QAH; -.
DR   PDBsum; 4QAP; -.
DR   PDBsum; 4QBE; -.
DR   PDBsum; 4QBW; -.
DR   PDBsum; 4Y14; -.
DR   PDBsum; 4ZRT; -.
DR   PDBsum; 5K9V; -.
DR   PDBsum; 5K9W; -.
DR   PDBsum; 5KA0; -.
DR   PDBsum; 5KA1; -.
DR   PDBsum; 5KA2; -.
DR   PDBsum; 5KA3; -.
DR   PDBsum; 5KA4; -.
DR   PDBsum; 5KA7; -.
DR   PDBsum; 5KA8; -.
DR   PDBsum; 5KA9; -.
DR   PDBsum; 5KAA; -.
DR   PDBsum; 5KAB; -.
DR   PDBsum; 5KAC; -.
DR   PDBsum; 5KAD; -.
DR   ProteinModelPortal; P18031; -.
DR   SMR; P18031; -.
DR   BioGrid; 111736; 102.
DR   DIP; DIP-38014N; -.
DR   IntAct; P18031; 128.
DR   MINT; MINT-441655; -.
DR   STRING; 9606.ENSP00000360683; -.
DR   BindingDB; P18031; -.
DR   ChEMBL; CHEMBL335; -.
DR   DrugBank; DB08783; (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid.
DR   DrugBank; DB04800; 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID.
DR   DrugBank; DB04525; 2-(Carboxymethoxy)-5-[(2s)-2-({(2s)-2-[(3-Carboxypropanoyl)Amino] -3-Phenylpropanoyl}Amino)-3-Oxo-3-(Pentylamino)Propyl]Benzoic Acid.
DR   DrugBank; DB02622; 2-(Oxalyl-Amino)-Benzoic Acid.
DR   DrugBank; DB07295; 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID.
DR   DrugBank; DB02436; 2-{4-[(2s)-2-[({[(1s)-1-Carboxy-2-Phenylethyl]Amino}Carbonyl)Amino]-3-Oxo-3-(Pentylamino)Propyl]Phenoxy}Malonic Acid.
DR   DrugBank; DB01734; 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid.
DR   DrugBank; DB03483; 4-Benzoylamino-4-{1-{1-Carbamoyl-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethylcarbamoyl}-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethylcarbamoyl}-Butyric Acid.
DR   DrugBank; DB07197; 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID.
DR   DrugBank; DB06829; 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID.
DR   DrugBank; DB07130; 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID.
DR   DrugBank; DB03714; 4-Carbamoyl-4-{[6-(Difluoro-Phosphono-Methyl)-Naphthalene-2-Carbonyl]-Amino}-Butyric Acid.
DR   DrugBank; DB07480; 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN.
DR   DrugBank; DB08001; 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID.
DR   DrugBank; DB07289; 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID.
DR   DrugBank; DB08397; 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID.
DR   DrugBank; DB04001; 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid.
DR   DrugBank; DB04204; [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid.
DR   DrugBank; DB02615; Compound 19.
DR   DrugBank; DB02014; Compound 9.
DR   DrugBank; DB03661; Cysteinesulfonic Acid.
DR   DrugBank; DB05506; ISIS 113715.
DR   DrugBank; DB08003; ISOTHIAZOLIDINONE ANALOG.
DR   DrugBank; DB04088; N-(Allyloxycarbonyl)-4-[N-(Carboxy-Formyl)-2-(Benzoic Acid)-Amino]-L-Phenylalaninyl-Amino-Butyloxy-(6-Hydroxy-Benzoic Acid Methyl Ester).
DR   DrugBank; DB02784; N-[4-(2-{2-[3-(2-Bromo-Acetylamino)-Propionylamino]-3-Hydroxy-Propionylamino}-Ethyl)-Phenyl]-Oxalamic Acid.
DR   DrugBank; DB07651; N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE.
DR   DrugBank; DB03557; N-{1-[5-(1-Carbamoyl-2-Mercapto-Ethylcarbamoyl)-Pentylcarbamoyl]-2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Ethyl}-3-{2-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Acetylamino}-Succinamic Acid.
DR   DrugBank; DB02662; Novo Nordisk a/S Compound.
DR   DrugBank; DB08371; PARA-(BENZOYL)-PHENYLALANINE.
DR   DrugBank; DB02977; PNU177836.
DR   DrugBank; DB02620; Sp7343-Sp7964.
DR   DrugBank; DB01133; Tiludronate.
DR   DrugBank; DB03154; {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid.
DR   DEPOD; P18031; -.
DR   iPTMnet; P18031; -.
DR   PhosphoSitePlus; P18031; -.
DR   SwissPalm; P18031; -.
DR   DMDM; 131467; -.
DR   OGP; P18031; -.
DR   EPD; P18031; -.
DR   MaxQB; P18031; -.
DR   PaxDb; P18031; -.
DR   PeptideAtlas; P18031; -.
DR   PRIDE; P18031; -.
DR   DNASU; 5770; -.
DR   Ensembl; ENST00000371621; ENSP00000360683; ENSG00000196396.
DR   GeneID; 5770; -.
DR   KEGG; hsa:5770; -.
DR   UCSC; uc002xvl.5; human.
DR   CTD; 5770; -.
DR   DisGeNET; 5770; -.
DR   GeneCards; PTPN1; -.
DR   H-InvDB; HIX0027718; -.
DR   HGNC; HGNC:9642; PTPN1.
DR   HPA; CAB009329; -.
DR   HPA; CAB015217; -.
DR   HPA; HPA012542; -.
DR   MalaCards; PTPN1; -.
DR   MIM; 176885; gene.
DR   neXtProt; NX_P18031; -.
DR   OpenTargets; ENSG00000196396; -.
DR   PharmGKB; PA33985; -.
DR   eggNOG; KOG0789; Eukaryota.
DR   eggNOG; COG5599; LUCA.
DR   GeneTree; ENSGT00870000136380; -.
DR   HOGENOM; HOG000273908; -.
DR   HOVERGEN; HBG008321; -.
DR   InParanoid; P18031; -.
DR   KO; K05696; -.
DR   OMA; DGPIKEE; -.
DR   OrthoDB; EOG091G082B; -.
DR   PhylomeDB; P18031; -.
DR   TreeFam; TF315897; -.
DR   BRENDA; 3.1.3.48; 2681.
DR   Reactome; R-HSA-354192; Integrin alphaIIb beta3 signaling.
DR   Reactome; R-HSA-6807004; Negative regulation of MET activity.
DR   Reactome; R-HSA-877312; Regulation of IFNG signaling.
DR   Reactome; R-HSA-8849472; PTK6 Down-Regulation.
DR   Reactome; R-HSA-912694; Regulation of IFNA signaling.
DR   Reactome; R-HSA-982772; Growth hormone receptor signaling.
DR   SABIO-RK; P18031; -.
DR   SignaLink; P18031; -.
DR   SIGNOR; P18031; -.
DR   ChiTaRS; PTPN1; human.
DR   EvolutionaryTrace; P18031; -.
DR   GeneWiki; PTPN1; -.
DR   GenomeRNAi; 5770; -.
DR   PMAP-CutDB; P18031; -.
DR   PRO; PR:P18031; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000196396; -.
DR   CleanEx; HS_PTPN1; -.
DR   ExpressionAtlas; P18031; baseline and differential.
DR   Genevisible; P18031; HS.
DR   GO; GO:0098554; C:cytoplasmic side of endoplasmic reticulum membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0097443; C:sorting endosome; ISS:BHF-UCL.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0046875; F:ephrin receptor binding; IPI:UniProtKB.
DR   GO; GO:0005158; F:insulin receptor binding; IEA:Ensembl.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; IEA:Ensembl.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; IMP:UniProtKB.
DR   GO; GO:0007257; P:activation of JUN kinase activity; IEA:Ensembl.
DR   GO; GO:0006987; P:activation of signaling protein activity involved in unfolded protein response; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0030968; P:endoplasmic reticulum unfolded protein response; IDA:UniProtKB.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0036498; P:IRE1-mediated unfolded protein response; IEA:Ensembl.
DR   GO; GO:0060397; P:JAK-STAT cascade involved in growth hormone signaling pathway; TAS:Reactome.
DR   GO; GO:1902236; P:negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; ISS:BHF-UCL.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; NAS:BHF-UCL.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IMP:CACAO.
DR   GO; GO:1903898; P:negative regulation of PERK-mediated unfolded protein response; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0009968; P:negative regulation of signal transduction; TAS:Reactome.
DR   GO; GO:0030948; P:negative regulation of vascular endothelial growth factor receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0035335; P:peptidyl-tyrosine dephosphorylation; IDA:UniProtKB.
DR   GO; GO:1990264; P:peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activity; ISS:BHF-UCL.
DR   GO; GO:0035791; P:platelet-derived growth factor receptor-beta signaling pathway; IMP:UniProtKB.
DR   GO; GO:1903896; P:positive regulation of IRE1-mediated unfolded protein response; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:2000646; P:positive regulation of receptor catabolic process; IMP:CACAO.
DR   GO; GO:0006470; P:protein dephosphorylation; IMP:CACAO.
DR   GO; GO:0030100; P:regulation of endocytosis; IDA:UniProtKB.
DR   GO; GO:1902202; P:regulation of hepatocyte growth factor receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0033157; P:regulation of intracellular protein transport; IMP:CACAO.
DR   GO; GO:0009966; P:regulation of signal transduction; IMP:UniProtKB.
DR   GO; GO:0060338; P:regulation of type I interferon-mediated signaling pathway; TAS:Reactome.
DR   Gene3D; 3.90.190.10; -; 1.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR000242; PTPase_domain.
DR   InterPro; IPR012265; Ptpn1/Ptpn2.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR003595; Tyr_Pase_cat.
DR   InterPro; IPR000387; TYR_PHOSPHATASE_dom.
DR   Pfam; PF00102; Y_phosphatase; 1.
DR   PIRSF; PIRSF000926; Tyr-Ptase_nr1; 1.
DR   PRINTS; PR00700; PRTYPHPHTASE.
DR   SMART; SM00194; PTPc; 1.
DR   SMART; SM00404; PTPc_motif; 1.
DR   SUPFAM; SSF52799; SSF52799; 1.
DR   PROSITE; PS00383; TYR_PHOSPHATASE_1; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
DR   PROSITE; PS50055; TYR_PHOSPHATASE_PTP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome;
KW   Direct protein sequencing; Endoplasmic reticulum; Hydrolase; Membrane;
KW   Oxidation; Phosphoprotein; Polymorphism; Protein phosphatase;
KW   Reference proteome; S-nitrosylation.
FT   CHAIN         1    435       Tyrosine-protein phosphatase non-receptor
FT                                type 1.
FT                                /FTId=PRO_0000094748.
FT   DOMAIN        3    277       Tyrosine-protein phosphatase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00160}.
FT   REGION      215    221       Substrate binding. {ECO:0000250}.
FT   ACT_SITE    215    215       Phosphocysteine intermediate.
FT   BINDING     181    181       Substrate.
FT   BINDING     262    262       Substrate. {ECO:0000250}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000269|PubMed:2546149}.
FT   MOD_RES      20     20       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   MOD_RES      50     50       Phosphoserine; by PKB/AKT1, CLK1 and
FT                                CLK2. {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:10480872,
FT                                ECO:0000269|PubMed:11579209}.
FT   MOD_RES      66     66       Phosphotyrosine; by EGFR.
FT                                {ECO:0000269|PubMed:9355745}.
FT   MOD_RES     215    215       Cysteine persulfide; alternate.
FT                                {ECO:0000269|PubMed:22169477}.
FT   MOD_RES     215    215       Cysteine sulfenic acid (-SOH); alternate.
FT                                {ECO:0000269|PubMed:12802338,
FT                                ECO:0000269|PubMed:12802339}.
FT   MOD_RES     215    215       Cysteine sulfinic acid (-SO2H);
FT                                alternate. {ECO:0000269|PubMed:12802339}.
FT   MOD_RES     215    215       S-nitrosocysteine; in reversibly
FT                                inhibited form.
FT                                {ECO:0000269|PubMed:22169477}.
FT   MOD_RES     242    242       Phosphoserine; by CLK1 and CLK2.
FT                                {ECO:0000269|PubMed:10480872}.
FT   MOD_RES     243    243       Phosphoserine; by CLK1 and CLK2.
FT                                {ECO:0000269|PubMed:10480872}.
FT   MOD_RES     352    352       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:8491187}.
FT   MOD_RES     363    363       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     365    365       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     368    368       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     378    378       Phosphoserine; by PKC.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:8491187}.
FT   MOD_RES     386    386       Phosphoserine; by CDK1.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:8491187}.
FT   CROSSLNK    215    216       N,N-(cysteine-1,S-diyl)serine (Cys-Ser);
FT                                in inhibited form.
FT                                {ECO:0000269|PubMed:12802338,
FT                                ECO:0000269|PubMed:12802339}.
FT   VARIANT     381    381       G -> S (in dbSNP:rs16995304).
FT                                /FTId=VAR_022013.
FT   VARIANT     387    387       P -> L (associated with low glucose
FT                                tolerance; dbSNP:rs16995309).
FT                                /FTId=VAR_022014.
FT   MUTAGEN      50     50       S->A,D: No phosphorylation.
FT                                {ECO:0000269|PubMed:10480872,
FT                                ECO:0000269|PubMed:11579209}.
FT   MUTAGEN     181    181       D->A: Substrate-trapping mutant.
FT                                {ECO:0000269|PubMed:22169477}.
FT   MUTAGEN     215    215       C->S: Catalytically inactive mutant;
FT                                abolishes sulfhydration.
FT                                {ECO:0000269|PubMed:22169477}.
FT   HELIX         3     13       {ECO:0000244|PDB:2CM2}.
FT   HELIX        16     26       {ECO:0000244|PDB:2CM2}.
FT   TURN         33     36       {ECO:0000244|PDB:2CM2}.
FT   HELIX        38     43       {ECO:0000244|PDB:2CM2}.
FT   STRAND       45     48       {ECO:0000244|PDB:2FJM}.
FT   TURN         53     55       {ECO:0000244|PDB:2CM2}.
FT   STRAND       56     58       {ECO:0000244|PDB:2CM2}.
FT   STRAND       61     63       {ECO:0000244|PDB:2F71}.
FT   STRAND       66     74       {ECO:0000244|PDB:2CM2}.
FT   TURN         75     78       {ECO:0000244|PDB:2CM2}.
FT   STRAND       79     84       {ECO:0000244|PDB:2CM2}.
FT   TURN         89     91       {ECO:0000244|PDB:2F71}.
FT   HELIX        92    102       {ECO:0000244|PDB:2CM2}.
FT   STRAND      106    109       {ECO:0000244|PDB:2CM2}.
FT   STRAND      113    115       {ECO:0000244|PDB:2CM2}.
FT   STRAND      118    121       {ECO:0000244|PDB:2CMB}.
FT   STRAND      128    130       {ECO:0000244|PDB:2CNE}.
FT   STRAND      133    135       {ECO:0000244|PDB:2CM2}.
FT   TURN        136    139       {ECO:0000244|PDB:2CM2}.
FT   STRAND      140    149       {ECO:0000244|PDB:2CM2}.
FT   STRAND      151    162       {ECO:0000244|PDB:2CM2}.
FT   TURN        163    165       {ECO:0000244|PDB:2CM2}.
FT   STRAND      168    176       {ECO:0000244|PDB:2CM2}.
FT   STRAND      181    183       {ECO:0000244|PDB:2CM2}.
FT   STRAND      186    188       {ECO:0000244|PDB:2CM2}.
FT   HELIX       189    200       {ECO:0000244|PDB:2CM2}.
FT   TURN        201    204       {ECO:0000244|PDB:2CM2}.
FT   STRAND      211    220       {ECO:0000244|PDB:2CM2}.
FT   HELIX       221    237       {ECO:0000244|PDB:2CM2}.
FT   STRAND      238    240       {ECO:0000244|PDB:3A5J}.
FT   HELIX       241    243       {ECO:0000244|PDB:2CM2}.
FT   HELIX       246    253       {ECO:0000244|PDB:2CM2}.
FT   TURN        254    256       {ECO:0000244|PDB:2CM2}.
FT   HELIX       264    281       {ECO:0000244|PDB:2CM2}.
FT   TURN        282    284       {ECO:0000244|PDB:2FJM}.
FT   HELIX       287    295       {ECO:0000244|PDB:2F71}.
FT   TURN        296    298       {ECO:0000244|PDB:2VEV}.
SQ   SEQUENCE   435 AA;  49967 MW;  802377DCD33F41FD CRC64;
     MEMEKEFEQI DKSGSWAAIY QDIRHEASDF PCRVAKLPKN KNRNRYRDVS PFDHSRIKLH
     QEDNDYINAS LIKMEEAQRS YILTQGPLPN TCGHFWEMVW EQKSRGVVML NRVMEKGSLK
     CAQYWPQKEE KEMIFEDTNL KLTLISEDIK SYYTVRQLEL ENLTTQETRE ILHFHYTTWP
     DFGVPESPAS FLNFLFKVRE SGSLSPEHGP VVVHCSAGIG RSGTFCLADT CLLLMDKRKD
     PSSVDIKKVL LEMRKFRMGL IQTADQLRFS YLAVIEGAKF IMGDSSVQDQ WKELSHEDLE
     PPPEHIPPPP RPPKRILEPH NGKCREFFPN HQWVKEETQE DKDCPIKEEK GSPLNAAPYG
     IESMSQDTEV RSRVVGGSLR GAQAASPAKG EPSLPEKDED HALSYWKPFL VNMCVATVLT
     AGAYLCYRFL FNSNT
//
